Advertisement

Systemic Dysregulation in the Development of Hepatocellular Carcinoma

  • Jianren Gu
  • Xianghuo He
  • Zhenfeng Zhang
  • Weijie Guo
  • Zhiao Chen
  • Yingjun Zhao

Abstract

Cancer is an ancient disease of multi-cellular organisms acquired in the history of evolution. For more than one century, cancer was defined as a disease of autonomous, abnormal growth of cells from an organ or tissue. Therefore, the majority of research and resources were focused on the cancer, especially cancer cells. In recent decades, an increasing body of evidence has emerged to indicate that carcinogenesis and cancer progressions involve systemic dysregulation, which may be the important driving force in cancer development as well as its progression. As we have emphasized in Chapter 1, we defined cancer as a systems disease which is characterized by abnormal cell growth in a defined tissue or organ and progressive systemic dysregulation.

Keywords

Hepatocellular Carcinoma Glioma Cell Nicotinic Acetylcholine Receptor Glutamate Transporter Cholinergic System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Antoni M H, Lutgendorf S K, Cole S W, et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer, 2006, 6: 240–248.PubMedCrossRefGoogle Scholar
  2. [2]
    Yuen M F, Hou J L, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol, 2009, 24: 346–353.PubMedCrossRefGoogle Scholar
  3. [3]
    Luo R H, Zhao Z X, Zhou X Y, et al. Risk factors for primary liver carcinoma in Chinese population. World J Gastroenterol, 2005, 11: 4431–4434.PubMedGoogle Scholar
  4. [4]
    Laconi E, Tomasi C, Curreli F, et al. Early exposure to restraint stress enhances chemical carcinogenesis in rat liver. Cancer Lett, 2000, 161: 215–220.PubMedCrossRefGoogle Scholar
  5. [5]
    Cao L, Liu X, Lin E J, et al. Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell, 2010, 142: 52–64.PubMedCrossRefGoogle Scholar
  6. [6]
    Clevenger C V, Furth P A, Hankinson S E, et al. The role of prolactin in mammary carcinoma. Endocr Rev, 2003, 24: 1–27.PubMedCrossRefGoogle Scholar
  7. [7]
    Pequeux C, Keegan B P, Hagelstein M T, et al. Oxytocin-and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer, 2004, 11: 871–885.PubMedCrossRefGoogle Scholar
  8. [8]
    Thaker P H, Han L Y, Kamat A A, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med, 2006, 12: 939–944.PubMedCrossRefGoogle Scholar
  9. [9]
    Wan D, Gong Y, Qin W, et al. Large-scale cDNA transfection screening for genes related to cancer development and progression. Proc Natl Acad Sci USA, 2004, 101: 15724–15729.PubMedCrossRefGoogle Scholar
  10. [10]
    Wang Y, Wang T, Shi X, et al. Analysis of acetylcholine, choline and butyrobetaine in human liver tissues by hydrophilic interaction liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal, 2008, 47: 870–875.PubMedCrossRefGoogle Scholar
  11. [11]
    Oben J A, Diehl A M. Sympathetic nervous system regulation of liver repair. Anat Rec A Discov Mol Cell Evol Biol, 2004, 280: 874–883.PubMedCrossRefGoogle Scholar
  12. [12]
    Wessler I, Kirkpatrick C J, Racke K. The cholinergic ‘pitfall’: acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol, 1999, 26: 198–205.PubMedCrossRefGoogle Scholar
  13. [13]
    Wessler I, Kilbinger H, Bittinger F, et al. The non-neuronal cholinergic system in humans: expression, function and pathophysiology. Life Sci, 2003, 72: 2055–2061.PubMedCrossRefGoogle Scholar
  14. [14]
    Wessler I, Kirkpatrick C J, Racke K. Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol Ther, 1998, 77: 59–79.PubMedCrossRefGoogle Scholar
  15. [15]
    Klein J, Holler T, Cappel E, et al. Release of choline from rat brain under hypoxia: contribution from phospholipase A2 but not from phospholipase D. Brain Res, 1993, 630: 337–340.PubMedCrossRefGoogle Scholar
  16. [16]
    Song P, Sekhon H S, Jia Y, et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res, 2003, 63: 214–221.PubMedGoogle Scholar
  17. [17]
    Trombino S, Cesario A, Margaritora S, et al. Alpha7-nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway. Cancer Res, 2004, 64: 135–145.PubMedCrossRefGoogle Scholar
  18. [18]
    Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol, 2004, 74: 363–396.PubMedCrossRefGoogle Scholar
  19. [19]
    Leonard S, Bertrand D. Neuronal nicotinic receptors: from structure to function. Nicotine Tob Res, 2001, 3: 203–223.PubMedCrossRefGoogle Scholar
  20. [20]
    Brejc K, Van Dijk W J, Klaassen R V, et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature, 2001, 411: 269–276.PubMedCrossRefGoogle Scholar
  21. [21]
    Moise L, Piserchio A, Basus V J, et al. NMR structural analysis of alpha-bungarotoxin and its complex with the principal alpha-neurotoxinbinding sequence on the alpha 7 subunit of a neuronal nicotinic acetylcholine receptor. J Biol Chem, 2002, 277: 12406–12417.PubMedCrossRefGoogle Scholar
  22. [22]
    Antil S, Servent D, Menez A. Variability among the sites by which curaremimetic toxins bind to torpedo acetylcholine receptor, as revealed by identification of the functional residues of alpha-cobratoxin. J Biol Chem, 1999, 274: 34851–34858.PubMedCrossRefGoogle Scholar
  23. [23]
    Berg D K, Conroy W G. Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons. J Neurobiol, 2002, 53: 512–523.PubMedCrossRefGoogle Scholar
  24. [24]
    Couturier S, Bertrand D, Matter J M, et al. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron, 1990, 5: 847–856.PubMedCrossRefGoogle Scholar
  25. [25]
    Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci, 2004, 25: 317–324.PubMedCrossRefGoogle Scholar
  26. [26]
    Miyazawa A, Fujiyoshi Y, Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature, 2003, 423: 949–955.PubMedCrossRefGoogle Scholar
  27. [27]
    Fucile S. Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium, 2004, 35: 1–8.PubMedCrossRefGoogle Scholar
  28. [28]
    Berridge M J, Lipp P, Bootman M D. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol, 2000, 1: 11–21.PubMedCrossRefGoogle Scholar
  29. [29]
    Thomas A P, Bird G S, Hajnoczky G, et al. Spatial and temporal aspects of cellular calcium signaling. FASEB J, 1996, 10: 1505–1517.PubMedGoogle Scholar
  30. [30]
    Albuquerque E X, Pereira E F, Alkondon M, et al. Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of receptor activity. J Recept Signal Transduct Res, 1997, 17: 243–266.PubMedCrossRefGoogle Scholar
  31. [31]
    Lev S, Moreno H, Martinez R, et al. Protein tyrosine kinase PYK2 involved in Ca2+-induced regulation of ion channel and MAP kinase functions. Nature, 1995, 376: 737–745.PubMedCrossRefGoogle Scholar
  32. [32]
    Nakayama H, Numakawa T, Ikeuchi T, et al. Nicotine-induced phosphorylation of extracellular signal-regulated protein kinase and CREB in PC12h cells. J Neurochem, 2001, 79: 489–498.PubMedCrossRefGoogle Scholar
  33. [33]
    Dajas-Bailador F A, Soliakov L, Wonnacott S. Nicotine activates the extracellular signal-regulated kinase 1/2 via the alpha7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones. J Neurochem, 2002, 80: 520–530.PubMedCrossRefGoogle Scholar
  34. [34]
    Sastry B V, Janson V E. Cholinergic markers in transformed trophoblast cells: BeWo and JAr cells. Cell Mol Biol (Noisy-le-grand), 1997, 43: 559–565.Google Scholar
  35. [35]
    Kamimura Y, Fujii T, Kojima H, et al. Nitric oxide (NO) synthase mRNA expression and NO production via muscarinic acetylcholine receptor-mediated pathways in the CEM, human leukemic T-cell line. Life Sci, 2003, 72: 2151–2154.PubMedCrossRefGoogle Scholar
  36. [36]
    Zhao Y J, Wang X Y, Wang T, et al. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology, 2011, 53: 493–503.PubMedCrossRefGoogle Scholar
  37. [37]
    Ahlquist R P. A study of the adrenotropic receptors. Am J Physiol, 1948, 153: 586–600.PubMedGoogle Scholar
  38. [38]
    Aantaa R, Jalonen J. Perioperative use of alpha2-adrenoceptor agonists and the cardiac patient. Eur J Anaesthesiol, 2006, 23: 361–372.PubMedCrossRefGoogle Scholar
  39. [39]
    Hein L, Altman J D, Kobilka B K. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature, 1999, 402: 181–184.PubMedCrossRefGoogle Scholar
  40. [40]
    Dixon R A, Kobilka B K, Strader D J, et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature, 1986, 321: 75–79.PubMedCrossRefGoogle Scholar
  41. [41]
    Kobilka B K, Dixon R A, Frielle T, et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA, 1987, 84: 46–50.PubMedCrossRefGoogle Scholar
  42. [42]
    Kyprianou N, Benning C M. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res, 2000, 60: 4550–4555.PubMedGoogle Scholar
  43. [43]
    Benning C M, Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptorindependent action. Cancer Res, 2002, 62: 597–602.PubMedGoogle Scholar
  44. [44]
    Siddiqui E J, Shabbir M, Thompson C S, et al. Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved? Anticancer Res, 2005, 25: 4281–4286.PubMedGoogle Scholar
  45. [45]
    Lin S C, Chueh S C, Hsiao C J, et al. Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle. Neoplasia, 2007, 9: 830–839.PubMedCrossRefGoogle Scholar
  46. [46]
    Liou S F, Lin H H, Liang J C, et al. Inhibition of human prostate cancer cells proliferation by a selective alpha1-adrenoceptor antagonist labedipinedilol-A involves cell cycle arrest and apoptosis. Toxicology, 2009, 256: 13–24.PubMedCrossRefGoogle Scholar
  47. [47]
    Kanda H, Ishii K, Ogura Y, et al. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer, 2008, 122: 444–451.PubMedCrossRefGoogle Scholar
  48. [48]
    Tatsuta M, Iishi H, Baba M, et al. Alpha 1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N′-nitro-Nnitrosoguanidine in Wistar rats. Int J Cancer, 1998, 77: 467–469.PubMedCrossRefGoogle Scholar
  49. [49]
    Al-Wadei H A, Schuller H M. Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas. J Pathol, 2009, 218: 437–445.PubMedCrossRefGoogle Scholar
  50. [50]
    Park P G, Merryman J, Orloff M, et al. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res, 1995, 55: 3504–3508.PubMedGoogle Scholar
  51. [51]
    Cruise J L, Knechtle S J, Bollinger R R, et al. Alpha 1-adrenergic effects and liver regeneration. Hepatology, 1987, 7: 1189–11894.PubMedCrossRefGoogle Scholar
  52. [52]
    Cruise J L, Houck K A, Michalopoulos G K. Induction of DNA synthesis in cultured rat hepatocytes through stimulation of alpha 1 adrenoreceptor by norepinephrine. Science, 1985, 227: 749–751.PubMedCrossRefGoogle Scholar
  53. [53]
    Bevilacqua M, Norbiato G, Chebat E, et al. Changes in alpha-1 and beta-2 adrenoceptor density in human hepatocellular carcinoma. Cancer, 1991, 67: 2543–2551.PubMedCrossRefGoogle Scholar
  54. [54]
    Leung T W, Yu S, Johnson P J, et al. Phase II study of the efficacy and safety of cisplatin-epinephrine injectable gel administered to patients with unresectable hepatocellular carcinoma. J Clin Oncol, 2003, 21: 652–658.PubMedCrossRefGoogle Scholar
  55. [55]
    Cavalheiro Ea L J, Turski L. Frontiers in excitatory amino acid research. New York: Alan R Liss, 1988.Google Scholar
  56. [56]
    Watkins J C, Evans R H. Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol, 1981, 21: 165–204.PubMedCrossRefGoogle Scholar
  57. [57]
    Beart P M, O’shea R D. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol, 2007, 150: 5–17.PubMedCrossRefGoogle Scholar
  58. [58]
    Kanai Y, Hediger M A. The glutamate and neutral amino acid transporter family: physiological and pharmacological implications. Eur J Pharmacol, 2003, 479: 237–247.PubMedCrossRefGoogle Scholar
  59. [59]
    Sato H, Tamba M, Ishii T, et al. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem, 1999, 274: 11455–11458.PubMedCrossRefGoogle Scholar
  60. [60]
    Sato H, Tamba M, Kuriyama-Matsumura K, et al. Molecular cloning and expression of human xCT, the light chain of amino acid transport system xc. Antioxid Redox Signal, 2000, 2: 665–571.PubMedCrossRefGoogle Scholar
  61. [61]
    Kim J Y, Kanai Y, Chairoungdua A, et al. Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochim Biophys Acta, 2001, 1512: 335–344.PubMedCrossRefGoogle Scholar
  62. [62]
    Okuno S, Sato H, Kuriyama-Matsumura K, et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer, 2003, 88: 951–956.PubMedCrossRefGoogle Scholar
  63. [63]
    Huang Y, Dai Z, Barbacioru C, et al. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res, 2005, 65: 7446–7454.PubMedCrossRefGoogle Scholar
  64. [64]
    Pin J P, Acher F. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord, 2002, 1: 297–317.PubMedCrossRefGoogle Scholar
  65. [65]
    Schoepp D D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther, 2001, 299: 12–20.PubMedGoogle Scholar
  66. [66]
    Ye Z C, Rothstein J D, Sontheimer H. Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci, 1999, 19: 10767–10777.PubMedGoogle Scholar
  67. [67]
    Ye Z C, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res, 1999, 59: 4383–4391.PubMedGoogle Scholar
  68. [68]
    Gegelashvili G, Civenni G, Racagni G, et al. Glutamate receptor agonists up-regulate glutamate transporter GLAST in astrocytes. Neuroreport, 1996, 8: 261–265.PubMedCrossRefGoogle Scholar
  69. [69]
    Gegelashvili G, Dehnes Y, Danbolt N C, et al. The high-affinity glutamate transporters GLT1, GLAST, and EAAT4 are regulated via different signalling mechanisms. Neurochem Int, 2000, 37: 163–170.PubMedCrossRefGoogle Scholar
  70. [70]
    Lyons S A, Chung W J, Weaver A K, et al. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res, 2007, 67: 9463–9471.PubMedCrossRefGoogle Scholar
  71. [71]
    Ishiuchi S, Tsuzuki K, Yoshida Y, et al. Blockage of Ca2+-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med, 2002, 8: 971–978.PubMedCrossRefGoogle Scholar
  72. [72]
    Rzeski W, Turski L, Ikonomidou C. Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA, 2001, 98: 6372–6377.PubMedCrossRefGoogle Scholar
  73. [73]
    D’onofrio M, Arcella A, Bruno V, et al. Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem, 2003, 84: 1288–1295.CrossRefGoogle Scholar
  74. [74]
    Pollock P M, Cohen-Solal K, Sood R, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet, 2003, 34: 108–112.PubMedCrossRefGoogle Scholar
  75. [75]
    Iacovelli L, Arcella A, Battaglia G, et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci, 2006, 26: 8388–8397.PubMedCrossRefGoogle Scholar
  76. [76]
    Yoo B C, Jeon E, Hong S H, et al. Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line. Clin Cancer Res, 2004, 10: 4176–4184.PubMedCrossRefGoogle Scholar
  77. [77]
    Chang H J, Yoo B C, Lim S B, et al. Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res, 2005, 11: 3288–3295.PubMedCrossRefGoogle Scholar
  78. [78]
    Park S Y, Lee S A, Han I H, et al. Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep, 2007, 17: 81–87.PubMedGoogle Scholar
  79. [79]
    Chen R S, Song Y M, Zhou Z Y, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene, 2009, 28: 599–609.PubMedCrossRefGoogle Scholar
  80. [80]
    Yang Y, Li C, Nie X, et al. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res, 2007, 6: 2605–2614.PubMedCrossRefGoogle Scholar
  81. [81]
    Watanabe M, Maemura K, Kanbara K, et al. GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol, 2002, 213: 1–47.PubMedCrossRefGoogle Scholar
  82. [82]
    Johnston G A. GABAA receptor pharmacology. Pharmacol Ther, 1996, 69: 173–198.PubMedCrossRefGoogle Scholar
  83. [83]
    Davies P A, Hanna M C, Hales T G, et al. Insensitivity to anaesthetic agents conferred by a class of GABA(A) receptor subunit. Nature, 1997, 385: 820–823.PubMedCrossRefGoogle Scholar
  84. [84]
    Mehta A K, Ticku M K. An update on GABAA receptors. Brain Res Brain Res Rev, 1999, 29: 196–217.PubMedCrossRefGoogle Scholar
  85. [85]
    Kaupmann K, Huggel K, Heid J, et al. Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature, 1997, 386: 239–246.PubMedCrossRefGoogle Scholar
  86. [86]
    Bettler B, Tiao J Y. Molecular diversity, trafficking and subcellular localization of GABAB receptors. Pharmacol Ther, 2006, 110: 533–543.PubMedCrossRefGoogle Scholar
  87. [87]
    Tatsuta M, Iishi H, Baba M, et al. Effect of gamma-butyrolactone on baclofen inhibition of gastric carcinogenesis induced by N-methyl-N’-nitro-N-nitrosoguanidine in Wistar rats. Oncology, 1992, 49: 123–126.PubMedCrossRefGoogle Scholar
  88. [88]
    Tatsuta M, Iishi H, Baba M, et al. Attenuation by the GABA receptor agonist baclofen of experimental carcinogenesis in rat colon by azoxymethane. Oncology, 1992, 49: 241–245.PubMedCrossRefGoogle Scholar
  89. [89]
    Kleinrok Z, Matuszek M, Jesipowicz J, et al. GABA content and GAD activity in colon tumors taken from patients with colon cancer or from xenografted human colon cancer cells growing as s.c. tumors in athymic nu/nu mice. J Physiol Pharmacol, 1998, 49: 303–310.PubMedGoogle Scholar
  90. [90]
    Maemura K, Yamauchi H, Hayasaki H, et al. Gamma-amino-butyric acid immunoreactivity in intramucosal colonic tumors. J Gastroenterol Hepatol, 2003, 18: 1089–1094.PubMedCrossRefGoogle Scholar
  91. [91]
    Opolski A, Mazurkiewicz M, Wietrzyk J, et al. The role of GABA-ergic system in human mammary gland pathology and in growth of transplantable murine mammary cancer. J Exp Clin Cancer Res, 2000, 19: 383–390.PubMedGoogle Scholar
  92. [92]
    Matuszek M, Jesipowicz M, Kleinrok Z. GABA content and GAD activity in gastric cancer. Med Sci Monit, 2001, 7: 377–381.PubMedGoogle Scholar
  93. [93]
    Bianchi L, De Micheli E, Bricolo A, et al. Extracellular levels of amino acids and choline in human high grade gliomas: an intraoperative microdialysis study. Neurochem Res, 2004, 29: 325–334.PubMedCrossRefGoogle Scholar
  94. [94]
    Roberts S S, Mori M, Pattee P, et al. GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma. J Clin Oncol, 2004, 22: 4127–4134.PubMedCrossRefGoogle Scholar
  95. [95]
    Jiang Y, Harlocker S L, Molesh D A, et al. Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays. Oncogene, 2002, 21: 2270–2282.PubMedCrossRefGoogle Scholar
  96. [96]
    Takehara A, Hosokawa M, Eguchi H, et al. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res, 2007, 67: 9704–9712.PubMedCrossRefGoogle Scholar
  97. [97]
    Azuma H, Inamoto T, Sakamoto T, et al. Gamma-aminobutyric acid as a promoting factor of cancer metastasis; induction of matrix metalloproteinase production is potentially its underlying mechanism. Cancer Res, 2003, 63: 8090–8096.PubMedGoogle Scholar
  98. [98]
    Joseph J, Niggemann B, Zaenker K S, et al. The neurotransmitter gammaaminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res, 2002, 62: 6467–6469.PubMedGoogle Scholar
  99. [99]
    Fava G, Marucci L, Glaser S, et al. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res, 2005, 65: 11437–11446.PubMedCrossRefGoogle Scholar
  100. [100]
    Thaker P H, Yokoi K, Jennings N B, et al. Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist nembutal. Cancer Biol Ther, 2005, 4: 753–758.PubMedCrossRefGoogle Scholar
  101. [101]
    Zhang M, Gong Y, Assy N, et al. Increased GABAergic activity inhibits alpha-fetoprotein mRNA expression and the proliferative activity of the HepG2 human hepatocellular carcinoma cell line. J Hepatol, 2000, 32: 85–91.PubMedCrossRefGoogle Scholar
  102. [102]
    Minuk G Y, Zhang M, Gong Y, et al. Decreased hepatocyte membrane potential differences and GABAA-beta3 expression in human hepatocellular carcinoma. Hepatology, 2007, 45: 735–745.PubMedCrossRefGoogle Scholar
  103. [103]
    Wang T, Huang W, Chen F. Baclofen, a GABAB receptor agonist, inhibits human hepatocellular carcinoma cell growth in vitro and in vivo. Life Sci, 2008, 82: 536–541.PubMedCrossRefGoogle Scholar
  104. [104]
    Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol, 2004, 4: 941–952.PubMedCrossRefGoogle Scholar
  105. [105]
    Gao F G, Wan Da F, Gu J R. Ex vivo nicotine stimulation augments the efficacy of therapeutic bone marrow-derived dendritic cell vaccination. Clin Cancer Res, 2007, 13: 3706–3712.PubMedCrossRefGoogle Scholar
  106. [106]
    Gao F G, Li H T, Li Z J, et al. Nicotine Stimulated Dendritic Cells Could Achieve Anti-Tumor Effects in Mouse Lung and Liver Cancer. J Clin Immunol, 2011, 31: 80–88.PubMedCrossRefGoogle Scholar

Copyright information

© Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Jianren Gu
    • 1
  • Xianghuo He
    • 1
  • Zhenfeng Zhang
    • 1
  • Weijie Guo
    • 1
  • Zhiao Chen
    • 1
  • Yingjun Zhao
    • 1
  1. 1.State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations